Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:IMRA

IMARA (IMRA) Stock Price, News & Analysis

IMARA logo

About IMARA Stock (NASDAQ:IMRA)

Advanced Chart

Key Stats

Today's Range
$55.64
$55.64
50-Day Range
$6.32
$25.28
52-Week Range
$0.97
$6.32
Volume
48 shs
Average Volume
138,364 shs
Market Capitalization
$1.46 billion
P/E Ratio
1,112.93
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2-related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas. IMARA Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Receive IMRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IMARA and its competitors with MarketBeat's FREE daily newsletter.

IMRA Stock News Headlines

Imara Blume
$2 Trillion Disappears Because of Fed's Secretive New Move
$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.
Imara 10% Owner Trades $336K In Company Stock
See More Headlines

IMRA Stock Analysis - Frequently Asked Questions

IMARA Inc. (NASDAQ:IMRA) posted its quarterly earnings data on Tuesday, November, 9th. The company reported ($2.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.64) by $1.44.

IMARA's stock reverse split before market open on Friday, February 24th 2023. The 1-4 reverse split was announced on Friday, February 24th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 24th 2023. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

IMARA (IMRA) raised $76 million in an initial public offering (IPO) on Thursday, March 12th 2020. The company issued 4,500,000 shares at $16.00-$18.00 per share. Morgan Stanley, Citigroup and SVB Leerink acted as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that IMARA investors own include NIO (NIO), Novavax (NVAX), NVIDIA (NVDA), Axsome Therapeutics (AXSM), Alibaba Group (BABA), AMC Entertainment (AMC) and BioXcel Therapeutics (BTAI).

Company Calendar

Last Earnings
11/09/2021
Today
4/26/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IMRA
Phone
N/A
Fax
N/A
Employees
41
Year Founded
N/A

Profitability

Trailing P/E Ratio
1,112.93
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$1.49 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
$0.74 per share
Price / Cash Flow
75.24
Book Value
$3.44 per share
Price / Book
16.17

Miscellaneous

Free Float
16,449,000
Market Cap
$1.46 billion
Optionable
Not Optionable
Beta
1.09
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:IMRA) was last updated on 4/26/2025 by MarketBeat.com Staff
From Our Partners